Revol B, Willeman T, Manceau M, Dumestre-Toulet V, Gaulier J, Fouilhe Sam-Lai N
JAMA Netw Open. 2023; 6(8):e2331398.
PMID: 37647066
PMC: 10469283.
DOI: 10.1001/jamanetworkopen.2023.31398.
Bertin C, Montigne E, Teixeira S, Ferrer F, Lauwerie L, Richard D
Harm Reduct J. 2023; 20(1):59.
PMID: 37106464
PMC: 10134660.
DOI: 10.1186/s12954-023-00781-2.
Bouquet E, Eiden C, Fauconneau B, Pion C, Pain S, Perault-Pochat M
Sci Rep. 2022; 12(1):16509.
PMID: 36192621
PMC: 9530152.
DOI: 10.1038/s41598-022-19197-2.
Laforgue E, Rousselet M, Claudon A, Aquizerate A, Jolliet P, Istvan M
Int J Environ Res Public Health. 2022; 19(15).
PMID: 35897285
PMC: 9331950.
DOI: 10.3390/ijerph19158920.
Eiden C, Roy S, Malafaye N, Lehmann M, Peyriere H
Fundam Clin Pharmacol. 2022; 36(6):1128-1132.
PMID: 35801616
PMC: 9796279.
DOI: 10.1111/fcp.12815.
Perception of the Regulatory Change for Zolpidem Prescription by French General Practitioners and Its Relation to Prescription Behavior.
Laforgue E, Istvan M, Schreck B, Mainguy M, Jolliet P, Grall-Bronnec M
J Clin Med. 2022; 11(8).
PMID: 35456269
PMC: 9032177.
DOI: 10.3390/jcm11082176.
Increase of high-risk tramadol use and harmful consequences in France from 2013 to 2018: Evidence from the triangulation of addictovigilance data.
Roussin A, Soeiro T, Fouque C, Jouanjus E, Frauger E, Fouilhe N
Br J Clin Pharmacol. 2022; 88(8):3789-3802.
PMID: 35318713
PMC: 9545570.
DOI: 10.1111/bcp.15323.
Early Detection of Prescription Drug Abuse Using Doctor Shopping Monitoring From Claims Databases: Illustration From the Experience of the French Addictovigilance Network.
Soeiro T, Lacroix C, Pradel V, Lapeyre-Mestre M, Micallef J
Front Psychiatry. 2021; 12:640120.
PMID: 34079478
PMC: 8165176.
DOI: 10.3389/fpsyt.2021.640120.
Gabapentinoid Abuse in France: Evidence on Health Consequences and New Points of Vigilance.
Tambon M, Ponte C, Jouanjus E, Fouilhe N, Micallef J, Lapeyre-Mestre M
Front Psychiatry. 2021; 12:639780.
PMID: 33613345
PMC: 7886797.
DOI: 10.3389/fpsyt.2021.639780.
Addictovigilance contribution during COVID-19 epidemic and lockdown in France.
Lapeyre-Mestre M, Boucher A, Daveluy A, Gibaja V, Jouanjus E, Mallaret M
Therapie. 2020; 75(4):343-354.
PMID: 32660776
PMC: 7309935.
DOI: 10.1016/j.therap.2020.06.006.
Consumption of psychoactive substances in prison: Between initiation and improvement, what trajectories occur after incarceration? COSMOS study data.
Rousselet M, Guerlais M, Caillet P, Le Geay B, Mauillon D, Serre P
PLoS One. 2019; 14(12):e0225189.
PMID: 31800580
PMC: 6892542.
DOI: 10.1371/journal.pone.0225189.
French national health insurance database analysis and field study focusing on the impact of secure prescription pads on zolpidem consumption and sedative drug misuse: ZORRO study protocol.
Gerardin M, Rousselet M, Caillet P, Grall-Bronnec M, Loue P, Jolliet P
BMJ Open. 2019; 9(6):e027443.
PMID: 31256026
PMC: 6609064.
DOI: 10.1136/bmjopen-2018-027443.
Comment on: An Insight Into Z-Drug Abuse and Dependence: An Examination of Reports to the European Medicines Agency Database of Suspected Adverse Drug Reactions.
Jouanjus E, Micallef J, Mallaret M, Lapeyre-Mestre M
Int J Neuropsychopharmacol. 2019; 22(8):528-530.
PMID: 31194866
PMC: 6672683.
DOI: 10.1093/ijnp/pyz033.
Identification of Somatic Disorders Related to Psychoactive Drug Use from an Inpatient Database in a French University Hospital.
Lafaurie M, Pochard L, Lotiron C, Molinier L, Lapeyre-Mestre M, Jouanjus E
Clin Drug Investig. 2018; 38(10):977-982.
PMID: 30047105
DOI: 10.1007/s40261-018-0679-4.
High opioids tolerance due to transmucosal fentanyl abuse.
Eiden C, Mathieu O, Donnadieu-Rigole H, Marrot C, Peyriere H
Eur J Clin Pharmacol. 2017; 73(9):1195-1196.
PMID: 28577225
DOI: 10.1007/s00228-017-2272-9.
Identifying Life-Threatening Admissions for Drug Dependence or Abuse (ILIADDA): Derivation and Validation of a Model.
Nguyen T, Boudemaghe T, Leguelinel-Blache G, Eiden C, Kinowski J, Le Manach Y
Sci Rep. 2017; 7:44428.
PMID: 28290530
PMC: 5349588.
DOI: 10.1038/srep44428.
Early signal of diverted use of tropicamide eye drops in France.
Ponte C, Pi C, Palmaro A, Jouanjus E, Lapeyre-Mestre M
Br J Clin Pharmacol. 2017; 83(8):1791-1800.
PMID: 28239898
PMC: 5510080.
DOI: 10.1111/bcp.13272.
Comment on: "Social Media Mining for Toxicovigilance: Automatic Monitoring of Prescription Medication Abuse from Twitter".
Jouanjus E, Mallaret M, Micallef J, Ponte C, Roussin A, Lapeyre-Mestre M
Drug Saf. 2017; 40(2):183-185.
PMID: 28070741
DOI: 10.1007/s40264-016-0497-7.
Disproportionality Analysis for the Assessment of Abuse and Dependence Potential of Pregabalin in the French Pharmacovigilance Database.
Bossard J, Ponte C, Dupouy J, Lapeyre-Mestre M, Jouanjus E
Clin Drug Investig. 2016; 36(9):735-742.
PMID: 27300651
DOI: 10.1007/s40261-016-0421-z.
Study protocol of the ESUB-MG cluster randomized trial: a pragmatic trial assessing the implementation of urine drug screening in general practice for buprenorphine maintained patients.
BMC Fam Pract. 2016; 17:24.
PMID: 26931763
PMC: 4774159.
DOI: 10.1186/s12875-016-0413-3.